Market Cap 206.46M
Revenue (ttm) 146.07M
Net Income (ttm) -196.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -134.21%
Debt to Equity Ratio -0.45
Volume 200,300
Avg Vol 454,314
Day's Range N/A - N/A
Shares Out 22.66M
Stochastic %K 39%
Beta 0.83
Analysts Strong Sell
Price Target $15.57

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 658 0600
Address:
85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States
Sauce27x
Sauce27x Jun. 11 at 7:12 PM
$KPTI are we finally gonna push thru 10!!!!
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 11 at 12:29 PM
The attachment is a history of all 62 new commercial-stage oncology focused bios since 1/1/2013, and what would have happened to you if you invested $1,000 in all 62 at the time of approval. Had you invested $1,000 in all 62 at the bio's closing share price the day after approval was announced, your $62,000 investment would be worth $60,008 today (excluding the time value of money). As we've posted time & again, 18 of the 62 were sold @ gains & 9 of the 62 were sold at a loss (using the bio's closing share price 1 day post approval). Our summary makes 1 adjustment to reflect those commercial-stage bios sold within 2 years after FDA approval & those that waited for more than 2 years. The data speaks for itself. The historical evidence is overwhelming, as is common sense, shareholder value of bios in this peer group is maximized via M&A exit within 2 years of FDA approval. $GERN $LEGN $KPTI $ADCT $KURA
4 · Reply
laaarsas
laaarsas Jun. 9 at 7:20 PM
$KPTI Tried again today. I contacted them in april about this. Still nothing. Have called and emailed several times.
0 · Reply
celebratelife
celebratelife Jun. 9 at 5:40 AM
$KPTI Board member Deepa Pakianathan dumped tons of shares at over 10 times current price, and again and again, and she's still a fucking director! Board's guard dog, horrible General Counsel Mike Mano tried to justify some weird "coincidence" as uncorrelated. Do these directors care about shareholders? I'd say, most of them: never have, never will, and funds are drying up to cover up toe indemnification clause so they'll be personally responsible for lawsuits regarding alleged breach of duties, from their personal funds, and most of these directors are mega loaded with assets so lots for shareholders to tap into if this useless Board and the horrible CEO Richard Paulson screw it up any more after having debilitated the stock as they got paid tons of money and even gave away our money - money we didn't have. They seem to have completely forgotten about their legal duties/accountability/liabilities.
0 · Reply
celebratelife
celebratelife Jun. 9 at 5:17 AM
$KPTI what's with that quarter mustache? at least he trimmed most of the beard he's apparently been hiding behind.
0 · Reply
celebratelife
celebratelife Jun. 8 at 6:44 PM
$KPTI I've never heard him add ANY value in all these useless investor calls he attends. Lousy CEO Richard Paulson has said how excited he is for 5 years now as he's made a TON of money (very exciting for him) as KPTI has been decimated under his lousy, irresponsible, incompetent non-leadership.
0 · Reply
celebratelife
celebratelife Jun. 8 at 6:19 PM
$KPTI's unofficial PR guy who gets the info before we do, posted that the horrible, value-destroyer CEO Richard Paulson had listed his big house for sale. He's been compensated around $30,000,000 in the last 5 fucking years KPTI stock got destroyed on his watch, as he splurged the hell out of our money on the fucking wasteful vacation-club style corporate culture, lack of financial discipline, lack of care, lack of sense of responsibility to his mandate to create shareholder value, to drive the bottom line, to act ethically for the benefit of the company that he's trusted to run. NO. It was more important for him to feed all their faces with catered daily free lunches, go on unnecessary trips, give tons of money to themselves in bonuses and big salaries despite ruining the stock, and raising money with toxic financing on horrible terms only a bunch of incompetent bozos would do, desperate to raise more to spend more - not to save and extend runway, but give it away to Dempseys et al.
0 · Reply
laaarsas
laaarsas Jun. 8 at 2:46 PM
$KPTI BICR PFS data anyone?
0 · Reply
ClassiTrader
ClassiTrader Jun. 7 at 10:00 PM
$KPTI keep an eye on this
0 · Reply
FlyontheCEOSwall
FlyontheCEOSwall Jun. 6 at 7:43 PM
$KPTI Fly on the wall listening closely to see if there are any discussions of a buyout in a few months.
1 · Reply
Latest News on KPTI
Karyopharm Therapeutics Transcript: Study result

Jun 2, 2026, 2:00 PM EDT - 9 days ago

Karyopharm Therapeutics Transcript: Study result


Karyopharm Therapeutics Press release: Study result

Jun 2, 2026, 2:00 PM EDT - 9 days ago

Karyopharm Therapeutics Press release: Study result


Karyopharm Therapeutics Slides: Study result

Jun 2, 2026, 2:00 PM EDT - 9 days ago

Karyopharm Therapeutics Slides: Study result


Karyopharm Therapeutics Transcript: AGM 2026

May 21, 2026, 9:00 AM EDT - 21 days ago

Karyopharm Therapeutics Transcript: AGM 2026


Karyopharm Therapeutics Slides: Corporate presentation

May 17, 2026, 7:00 AM EDT - 25 days ago

Karyopharm Therapeutics Slides: Corporate presentation


Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)

2026-05-14T12:06:55.000Z - 4 weeks ago

Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)


Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M

2026-05-14T12:04:59.000Z - 4 weeks ago

Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M


Karyopharm Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:00 AM EDT - 4 weeks ago

Karyopharm Therapeutics Earnings Call Transcript: Q1 2026


Karyopharm Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 4 weeks ago

Karyopharm Therapeutics Earnings release: Q1 2026


Karyopharm Therapeutics Slides: Q1 2026

May 14, 2026, 8:00 AM EDT - 4 weeks ago

Karyopharm Therapeutics Slides: Q1 2026


Karyopharm Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 4 weeks ago

Karyopharm Therapeutics Quarterly report: Q1 2026


Karyopharm to Participate at Upcoming Investor Conferences

May 12, 2026, 7:30 AM EDT - 4 weeks ago

Karyopharm to Participate at Upcoming Investor Conferences


Karyopharm files $400M mixed securities shelf

2026-05-04T20:43:12.000Z - 5 weeks ago

Karyopharm files $400M mixed securities shelf


Karyopharm Therapeutics Slides: Corporate presentation

Apr 16, 2026, 7:00 AM EDT - 2 months ago

Karyopharm Therapeutics Slides: Corporate presentation


Karyopharm Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Proxy statement: Proxy filing


Karyopharm price target lowered to $16 from $23 at RBC Capital

2026-04-07T15:11:06.000Z - 2 months ago

Karyopharm price target lowered to $16 from $23 at RBC Capital


Karyopharm price target lowered to $8 from $12 at Piper Sandler

2026-03-30T11:31:21.000Z - 2 months ago

Karyopharm price target lowered to $8 from $12 at Piper Sandler


Karyopharm price target lowered to $15 from $21 at Baird

2026-03-25T11:26:32.000Z - 2 months ago

Karyopharm price target lowered to $15 from $21 at Baird


Karyopharm Therapeutics Transcript: Study result

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Transcript: Study result


Karyopharm Therapeutics Press release: Study result

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Press release: Study result


Karyopharm Therapeutics Slides: Study result

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Slides: Study result


Karyopharm announces $30M private placement

2026-03-24T11:05:33.000Z - 2 months ago

Karyopharm announces $30M private placement


Karyopharm initiated with a Buy at Rodman & Renshaw

2026-03-09T20:20:12.000Z - 3 months ago

Karyopharm initiated with a Buy at Rodman & Renshaw


Karyopharm Therapeutics Transcript: EGM 2026

Feb 18, 2026, 9:00 AM EST - 4 months ago

Karyopharm Therapeutics Transcript: EGM 2026


Karyopharm Therapeutics Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:00 AM EST - 4 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q4 2025


Karyopharm Therapeutics Annual report: Q4 2025

Feb 12, 2026, 8:00 AM EST - 4 months ago

Karyopharm Therapeutics Annual report: Q4 2025


Karyopharm Therapeutics Earnings release: Q4 2025

Feb 12, 2026, 8:00 AM EST - 4 months ago

Karyopharm Therapeutics Earnings release: Q4 2025


Karyopharm Therapeutics Slides: Q4 2025

Feb 12, 2026, 8:00 AM EST - 4 months ago

Karyopharm Therapeutics Slides: Q4 2025


Karyopharm reports Q4 EPS ($5.71) vs. ($3.67) last year

2026-02-12T12:46:18.000Z - 4 months ago

Karyopharm reports Q4 EPS ($5.71) vs. ($3.67) last year


Karyopharm initiated with an Overweight at Cantor Fitzgerald

2026-02-05T10:10:10.000Z - 4 months ago

Karyopharm initiated with an Overweight at Cantor Fitzgerald


Karyopharm sees FY25 revenue $145M, consensus $147.83M

2026-01-12T12:17:22.000Z - 5 months ago

Karyopharm sees FY25 revenue $145M, consensus $147.83M


Karyopharm Therapeutics Proxy statement: Proxy Filing

Jan 9, 2026, 7:00 AM EST - 5 months ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 30, 2025, 7:00 AM EST - 5 months ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm to Participate in Baird's Biotech Discovery Series

Dec 8, 2025, 7:00 AM EST - 6 months ago

Karyopharm to Participate in Baird's Biotech Discovery Series


Karyopharm Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q3 2025


Karyopharm Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

Karyopharm Therapeutics Earnings release: Q3 2025


Karyopharm Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

Karyopharm Therapeutics Quarterly report: Q3 2025


Karyopharm Therapeutics Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

Karyopharm Therapeutics Slides: Q3 2025


Karyopharm Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q2 2025


Karyopharm Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Karyopharm Therapeutics Quarterly report: Q2 2025


Karyopharm Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Karyopharm Therapeutics Earnings release: Q2 2025


Karyopharm Therapeutics Slides: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Karyopharm Therapeutics Slides: Q2 2025


Karyopharm Therapeutics Slides: FY 2025

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Karyopharm Therapeutics Slides: FY 2025


Karyopharm Therapeutics Slides: Corporate Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Corporate Presentation


Karyopharm Therapeutics Transcript: AGM 2025

May 28, 2025, 9:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: AGM 2025


Karyopharm Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q1 2025


Karyopharm Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Quarterly report: Q1 2025


Karyopharm Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Earnings release: Q1 2025


Karyopharm Therapeutics Slides: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Slides: Q1 2025


Karyopharm Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 24, 2025, 8:40 AM EST - 1 year ago

Karyopharm Announces 1-for-15 Reverse Stock Split


Karyopharm Therapeutics Earnings Call Transcript: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q4 2024


Karyopharm Therapeutics Annual report: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Annual report: Q4 2024


Karyopharm Therapeutics Earnings release: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings release: Q4 2024


Karyopharm Therapeutics Slides: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Slides: Q4 2024


Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 16, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 5, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q3 2024


Karyopharm Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Quarterly report: Q3 2024


Karyopharm Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings release: Q3 2024


Karyopharm Therapeutics Slides: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Slides: Q3 2024


Karyopharm Therapeutics Transcript: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: Study Update


Karyopharm Therapeutics Press release: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Press release: Study Update


Karyopharm Therapeutics Slides: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Study Update


Karyopharm Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Earnings Call Transcript: Q2 2024


Karyopharm Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Quarterly report: Q2 2024


Karyopharm Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Earnings release: Q2 2024


Karyopharm Therapeutics Slides: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Slides: Q2 2024


Sauce27x
Sauce27x Jun. 11 at 7:12 PM
$KPTI are we finally gonna push thru 10!!!!
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 11 at 12:29 PM
The attachment is a history of all 62 new commercial-stage oncology focused bios since 1/1/2013, and what would have happened to you if you invested $1,000 in all 62 at the time of approval. Had you invested $1,000 in all 62 at the bio's closing share price the day after approval was announced, your $62,000 investment would be worth $60,008 today (excluding the time value of money). As we've posted time & again, 18 of the 62 were sold @ gains & 9 of the 62 were sold at a loss (using the bio's closing share price 1 day post approval). Our summary makes 1 adjustment to reflect those commercial-stage bios sold within 2 years after FDA approval & those that waited for more than 2 years. The data speaks for itself. The historical evidence is overwhelming, as is common sense, shareholder value of bios in this peer group is maximized via M&A exit within 2 years of FDA approval. $GERN $LEGN $KPTI $ADCT $KURA
4 · Reply
laaarsas
laaarsas Jun. 9 at 7:20 PM
$KPTI Tried again today. I contacted them in april about this. Still nothing. Have called and emailed several times.
0 · Reply
celebratelife
celebratelife Jun. 9 at 5:40 AM
$KPTI Board member Deepa Pakianathan dumped tons of shares at over 10 times current price, and again and again, and she's still a fucking director! Board's guard dog, horrible General Counsel Mike Mano tried to justify some weird "coincidence" as uncorrelated. Do these directors care about shareholders? I'd say, most of them: never have, never will, and funds are drying up to cover up toe indemnification clause so they'll be personally responsible for lawsuits regarding alleged breach of duties, from their personal funds, and most of these directors are mega loaded with assets so lots for shareholders to tap into if this useless Board and the horrible CEO Richard Paulson screw it up any more after having debilitated the stock as they got paid tons of money and even gave away our money - money we didn't have. They seem to have completely forgotten about their legal duties/accountability/liabilities.
0 · Reply
celebratelife
celebratelife Jun. 9 at 5:17 AM
$KPTI what's with that quarter mustache? at least he trimmed most of the beard he's apparently been hiding behind.
0 · Reply
celebratelife
celebratelife Jun. 8 at 6:44 PM
$KPTI I've never heard him add ANY value in all these useless investor calls he attends. Lousy CEO Richard Paulson has said how excited he is for 5 years now as he's made a TON of money (very exciting for him) as KPTI has been decimated under his lousy, irresponsible, incompetent non-leadership.
0 · Reply
celebratelife
celebratelife Jun. 8 at 6:19 PM
$KPTI's unofficial PR guy who gets the info before we do, posted that the horrible, value-destroyer CEO Richard Paulson had listed his big house for sale. He's been compensated around $30,000,000 in the last 5 fucking years KPTI stock got destroyed on his watch, as he splurged the hell out of our money on the fucking wasteful vacation-club style corporate culture, lack of financial discipline, lack of care, lack of sense of responsibility to his mandate to create shareholder value, to drive the bottom line, to act ethically for the benefit of the company that he's trusted to run. NO. It was more important for him to feed all their faces with catered daily free lunches, go on unnecessary trips, give tons of money to themselves in bonuses and big salaries despite ruining the stock, and raising money with toxic financing on horrible terms only a bunch of incompetent bozos would do, desperate to raise more to spend more - not to save and extend runway, but give it away to Dempseys et al.
0 · Reply
laaarsas
laaarsas Jun. 8 at 2:46 PM
$KPTI BICR PFS data anyone?
0 · Reply
ClassiTrader
ClassiTrader Jun. 7 at 10:00 PM
$KPTI keep an eye on this
0 · Reply
FlyontheCEOSwall
FlyontheCEOSwall Jun. 6 at 7:43 PM
$KPTI Fly on the wall listening closely to see if there are any discussions of a buyout in a few months.
1 · Reply
celebratelife
celebratelife Jun. 5 at 10:15 PM
$KPTI Richard Paulson, Mike Mano, Barry Greene and the rest of the value destroyers have paralyzed this company while they've gotten paid huge amounts. Another 4.5 day week at the KaryoFUN vacation club, and Paulson got another $25,000+ cash ++ for doing jack shit to drive value, after years of wasting our money with irresponsible, incompetent, self-centered, mismanagement, as it appears based on results. The Board is responsible and will be held to account.
0 · Reply
celebratelife
celebratelife Jun. 4 at 7:31 PM
$KPTI more money wasted on useless travel. Seems not even one person attended this horribly useless presentation. Paulson even has the nerves to even mention cash runway after DESTROYING IT by his splurging, mismanagement, and lack of financiala discipline.
0 · Reply
celebratelife
celebratelife Jun. 4 at 7:26 PM
$KPTI Richard Paulson today at Jefferies - the man who destroyed KPTI by splurging our assets, mismanagement, lack of financial discipline, lack of professional ethics to abide by his mandate to drive shareholder value, DESTROYED THE HELL OUT OF KPTI which is now over 95% lower, and shorts have made a killing, and long term investors' money in KPTI devastated to fucking PENNIE as Paulson and the lousy, unethical, incompetent Board that allegedly breached their duties as well. Paulson even gave away large sums of money we did not have. Absolutely ZERO royalty to shareholders as he was destroying shareholder value for years and got paid millions -- compensated to the tune of some 30 million dollars in the fucking hell of a 5 years he's been there. Wall Street knows what he's about as a lousy CEO except for short sellers who love him. FIRING him is long overdue -- the Board of Directors should do the right thing and fire his ass. You too Mike Mano!
0 · Reply
elmono
elmono Jun. 3 at 4:01 PM
$KPTI one of the most hated names in bio land….and rightfully so…..therefore one of the most undervalued
1 · Reply
InkaTwits
InkaTwits Jun. 3 at 1:10 PM
$KPTI BO in the making.
0 · Reply
profDB
profDB Jun. 2 at 10:17 PM
$KPTI nothing was new at the presentation. Buyers for possible news Quit….
0 · Reply
Heywood_Jablomi
Heywood_Jablomi Jun. 2 at 8:18 PM
$KPTI nice close… what’s cooking here?
0 · Reply
focafoca99
focafoca99 Jun. 2 at 7:23 PM
$KPTI shared late-breaking ASCO results from its Phase 3 SENTRY trial showing selinexor plus ruxolitinib improves spleen volume reduction
0 · Reply
celebratelife
celebratelife Jun. 2 at 5:38 PM
$KPTI This stock / company has cancer because of what has been done to it by an incompetent, self-serving, horrible CEO and Board who've always thrown shareholders under the bus as they splurged the hell out of our assets and ran our company like a fucking charity that keeps giving to themselves, insiders, and likes of Dempsey. These unethical value destroyers even gave multiple 250k+ donations of our money which we didn't have and they raised it with toxic financing after paralyzing the stock by dilution for years to support their fucking splurging, always assuming there's no accountability - that our money was theirs to spend instead of being managed based on their fiduciary duties which has not been a part of their mindset at all apparently, and even now that shit has hit the fan, Richard Paulson's version of dealing with the fucking mess he's made is to repeat: financial discipline, sense of urgency. He thinks we're fucking dumb to not see right through his BS, lousy track record.
0 · Reply
mich1282
mich1282 Jun. 2 at 2:52 PM
$KPTI adding because this is so dumb
0 · Reply
focafoca99
focafoca99 Jun. 2 at 2:09 PM
$KPTI announced its Phase 3 SENTRY trial abstract was selected for a late‑breaking oral presentation at EHA 2026.
0 · Reply
Linda1155
Linda1155 Jun. 2 at 12:19 PM
$KPTI Multiple Phase 3 catalysts in 2026,,
0 · Reply